In addition to the repurposing of nortriptyline, German biotech company MODAG, supported by Cure Parkinson’s, announced favourable Phase 1 results for their alpha-synuclein targeted drug ‘Anle138b’
The company has very recently partnered with the Pharmaceutical company TEVA to take this drug further in clinical development. Hopefully we will learn more about their next clinical trial in 2022.
Finally, the pharmaceutical company UCB announced their partnering with Swiss pharmaceutical company Novartis to develop another alpha-synuclein targeting agent called UCB0599. This alpha-synuclein clumping inhibitor is currently in Phase 2 clinical testing, and we look forward with interest to the results of this important trial.
We are sorry that this content was not useful for you
Let us improve this content
Can you tell us how we can improve this content?